PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Wisskirchen, K. ; Kah, J.* ; Malo, A. ; Asen, T. ; Volz, T.* ; Allweiss, L.* ; Wettengel, J.M.* ; Lütgehetmann, M.* ; Urban, S.* ; Bauer, T. ; Dandri, M.* ; Protzer, U.

T cell receptor grafting allows virological control of hepatitis B virus infection.

J. Clin. Invest. 130, 2932-2945 (2019)
Publ. Version/Full Text Postprint Research data DOI PMC
Open Access Gold
T cell therapy is a promising means to treat chronic hepatitis B virus (HBV) infection and HBV-associated hepatocellular carcinoma. T cells engineered to express an HBV-specific T cell receptor (TCR) may cure an HBV infection upon adoptive transfer. We investigated the therapeutic potential and safety of T cells stably expressing high-affinity HBV envelope- or core-specific TCRs recognizing European and Asian HLA-A2 subtypes. Both CD8(+) and CD4(+) T cells from healthy donors and patients with chronic hepatitis B became polyfunctional effector cells when grafted with HBV-specific TCRs and eliminated HBV from infected HepG2-NTCP cell cultures. A single transfer of TCR-grafted T cells into HBV-infected, humanized mice controlled HBV infection, and virological markers declined by 4 to 5 log or below the detection limit. Engineered T cells specifically cleared infected hepatocytes without damaging noninfected cells when, as in a typical clinical setting, only a minority of hepatocytes were infected. Cell death was compensated by hepatocyte proliferation, and alanine amino transferase levels peaking between days 5 and 7 normalized again thereafter. Cotreatment with the entry inhibitor myrcludex B ensured long-term control of HBV infection. Thus, T cells stably transduced with highly functional TCRs have the potential to mediate clearance of HBV-infected cells, causing limited liver injury.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
12.282
2.462
32
43
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Hepatitis ; Immunology ; Immunotherapy ; T Cells ; Virology; Chimeric Antigen Receptor; Humanized Mice; Cancer Regression; Adoptive Transfer; Viral Clearance; Immunity; Cd8(+); Replication; Hepatocytes; Expression
Language english
Publication Year 2019
HGF-reported in Year 2019
ISSN (print) / ISBN 0021-9738
e-ISSN 1558-8238
Journal Journal of Clinical Investigation
Quellenangaben Volume: 130, Issue: 7, Pages: 2932-2945 Article Number: , Supplement: ,
Publisher American Society of Clinical Investigation
Publishing Place 2015 Manchester Rd, Ann Arbor, Mi 48104 Usa
Reviewing status Peer reviewed
Institute(s) Institute of Virology (VIRO)
POF-Topic(s) 30203 - Molecular Targets and Therapies
Research field(s) Immune Response and Infection
PSP Element(s) G-502700-003
G-502700-002
DOI 10.1172/JCI120228
WOS ID WOS:000473326500032
PubMed ID 31039136
Erfassungsdatum 2019-05-10
[➜Report correction]